Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial

医学 白细胞介素1受体拮抗剂 安慰剂 受体拮抗剂 双盲 敌手 败血症 内科学 随机对照试验 重组DNA 白细胞介素 胃肠病学 受体 细胞因子 病理 替代医学 基因 化学 生物化学
作者
Charles J. Fisher
出处
期刊:JAMA [American Medical Association]
卷期号:271 (23): 1836-1836 被引量:1226
标识
DOI:10.1001/jama.1994.03510470040032
摘要

OBJECTIVE: To further define the safety and efficacy of recombinant human interleukin 1 receptor antagonist (rhIL-1ra) in the treatment of sepsis syndrome. STUDY DESIGN: Randomized, double-blind, placebo-controlled, multicenter, multinational clinical trial. POPULATION: A total of 893 patients with sepsis syndrome received an intravenous loading dose of rhIL-1ra, 100 mg, or placebo followed by a continuous 72-hour intravenous infusion of rhIL-1ra (1.0 or 2.0 mg/kg per hour) or placebo. OUTCOME MEASURE: Twenty-eight-day all-cause mortality. RESULTS: There was not a significant increase in survival time for rhIL-1ra treatment compared with placebo among all patients who received the study medication (n = 893; generalized Wilcoxon statistic, P = .22) or among patients with shock at study entry (n = 713; generalized Wilcoxon statistic, P = .23), the two primary efficacy analyses specified a priori for this trial. Results from secondary analyses suggest an increase in survival time with rhIL-1ra treatment among patients with dysfunction of one or more organs (n = 563; linear dose-response, P = .009). Retrospective analysis demonstrated an increase in survival time with rhIL-1ra treatment among patients with a predicted risk of mortality of 24% or greater (n = 580; linear dose-response, P = .005) as well as among patients with both dysfunction of one or more organs and a predicted risk of mortality of 24% or greater (n = 411; linear dose-response, P = .002). CONCLUSIONS: There was not a statistically significant increase in survival time for rhIL-1ra treatment compared with placebo among all patients who received the study medication or among patients with shock at study entry. Secondary and retrospective analyses of efficacy suggest that treatment with rhIL-1ra results in a dose-related increase in survival time among patients with sepsis who have organ dysfunction and/or a predicted risk of mortality of 24% or greater.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
1秒前
朋友发布了新的文献求助10
1秒前
2秒前
ZCTMWY发布了新的文献求助10
2秒前
星辰大海的应助被年年采纳,获得10
3秒前
nuoyefenfei发布了新的文献求助10
3秒前
3秒前
秋风的应助被徐世业采纳,获得20
4秒前
田様的应助被gouerde采纳,获得10
5秒前
369ninja发布了新的文献求助10
5秒前
thesky发布了新的文献求助10
6秒前
健忘兔子发布了新的文献求助10
6秒前
7秒前
传奇3的应助被Lu采纳,获得10
9秒前
jiawei1026完成签到,获得积分10
9秒前
初景发布了新的文献求助10
11秒前
无敌干扰素完成签到,获得积分10
11秒前
bkagyin的应助被嘎嘣脆采纳,获得10
12秒前
余香的应助被勤奋的翠绿采纳,获得10
13秒前
月见发布了新的文献求助10
13秒前
13秒前
霸气小松鼠关注了科研通微信公众号
13秒前
13秒前
123456789完成签到,获得积分10
14秒前
小马甲的应助被机智毛豆采纳,获得10
14秒前
FashionBoy的应助被psybrain9527采纳,获得10
15秒前
斯文败类的应助被biowzf采纳,获得10
15秒前
16秒前
Ava的应助被李细细采纳,获得10
17秒前
冯小路发布了新的文献求助10
17秒前
18秒前
18秒前
18秒前
18秒前
瓶子君152发布了新的文献求助10
19秒前
芋泥啵啵发布了新的文献求助10
20秒前
Hello的应助被mmm采纳,获得10
20秒前
jin发布了新的文献求助10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184240
求助须知:如何正确求助?哪些是违规求助? 9573297
关于积分的说明 21830585
捐赠科研通 7781300
什么是DOI,文献DOI怎么找? 3434285
关于科研通互助平台的介绍 2558389
邀请新用户注册赠送积分活动 2480814